Table 7.
COVID-19 Vaccines Side Effects of Participating German Healthcare Workers Stratified by Gender, February–March 2021 (n = 596).
| Variable | Outcome | mRNA-Based Vaccine | Viral Vector Vaccine | ||||
|---|---|---|---|---|---|---|---|
| Female | Male | Sig. | Female | Male | Sig. | ||
| Local SE | Injection Site Pain | 272 (77.9%) | 93 (76.2%) | 0.697 | 63 (75%) | 23 (56.1%) | 0.032 |
| Injection Site Swelling | 61 (17.5%) | 25 (20.5%) | 0.458 | 15 (17.9%) | 5 (12.2%) | 0.418 | |
| Injection Site Redness | 35 (10%) | 15 (12.3%) | 0.484 | 7 (8.3%) | 4 (9.8%) | 0.792 | |
| Intensity (μ ± SD) | 1.05 ± 0.80 | 1.09 ± 0.83 | 0.715 | 1.01 ± 0.75 | 0.78 ± 0.91 | 0.033 | |
| Total | 273 (78.2%) | 95 (77.9%) | 0.935 | 65 (77.4%) | 23 (56.1%) | 0.014 | |
| Systemic SE | Fever | 37 (10.6%) | 9 (7.4%) | 0.302 | 45 (53.6%) | 15 (36.6%) | 0.074 |
| Chills | 52 (14.9%) | 14 (11.5%) | 0.348 | 51 (60.7%) | 21 (51.2%) | 0.313 | |
| Headache/Fatigue | 179 (51.3%) | 47 (38.5%) | 0.015 | 68 (81%) | 25 (61%) | 0.016 | |
| Muscle Pain | 99 (28.4%) | 33 (27%) | 0.780 | 47 (56%) | 19 (46.3%) | 0.312 | |
| Joint Pain | 55 (15.8%) | 12 (9.8%) | 0.107 | 44 (52.4%) | 15 (36.6%) | 0.097 | |
| Nausea | 28 (8%) | 10 (8.2%) | 0.952 | 19 (22.6%) | 7 (17.1%) | 0.473 | |
| Malaise | 64 (18.3%) | 24 (19.7%) | 0.745 | 43 (51.2%) | 18 (43.9%) | 0.444 | |
| Lymphadenopathy | 36 (10.3%) | 6 (4.9%) | 0.072 | 7 (8.3%) | 6 (14.6%) | 0.351 * | |
| Intensity (μ ± SD) | 1.58 ± 1.81 | 1.27 ± 1.56 | 0.142 | 3.86 ± 2.14 | 3.07 ± 2.41 | 0.079 | |
| Total | 219 (62.8%) | 68 (55.7%) | 0.172 | 77 (91.7%) | 32 (78%) | 0.032 | |
| Severe SE | Total | 2 (0.6%) | 0 (0%) | 1.000 * | 3 (3.6%) | 1 (2.4%) | 1.000 * |
| Oral SE | Total | 41 (11.7%) | 18 (14.8%) | 0.388 | 31 (36.9%) | 16 (39%) | 0.818 |
| Skin-related SE | Total | 13 (3.7%) | 0 (0%) | 0.129 | 5 (6%) | 2 (4.9%) | 1.000 * |
Chi-squared test, Fisher’s exact test (*) and Mann–Whitney test were used with a significance level of <0.05.